CO2023000199A2 - Péptidos funcionalizados como agentes antivirales - Google Patents
Péptidos funcionalizados como agentes antiviralesInfo
- Publication number
- CO2023000199A2 CO2023000199A2 CONC2023/0000199A CO2023000199A CO2023000199A2 CO 2023000199 A2 CO2023000199 A2 CO 2023000199A2 CO 2023000199 A CO2023000199 A CO 2023000199A CO 2023000199 A2 CO2023000199 A2 CO 2023000199A2
- Authority
- CO
- Colombia
- Prior art keywords
- formula
- pharmaceutically acceptable
- antiviral agents
- subject
- compound
- Prior art date
Links
- 239000003443 antiviral agent Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063054048P | 2020-07-20 | 2020-07-20 | |
| PCT/US2021/042193 WO2022020242A1 (en) | 2020-07-20 | 2021-07-19 | Functionalized peptides as antiviral agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023000199A2 true CO2023000199A2 (es) | 2023-04-17 |
Family
ID=79729492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0000199A CO2023000199A2 (es) | 2020-07-20 | 2023-01-11 | Péptidos funcionalizados como agentes antivirales |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20220033383A1 (https=) |
| EP (2) | EP4635972A3 (https=) |
| JP (2) | JP7795521B2 (https=) |
| KR (1) | KR20230069090A (https=) |
| CN (1) | CN116348477A (https=) |
| AU (1) | AU2021313130A1 (https=) |
| BR (1) | BR112022026899A2 (https=) |
| CA (1) | CA3173964A1 (https=) |
| CL (1) | CL2023000167A1 (https=) |
| CO (1) | CO2023000199A2 (https=) |
| DE (3) | DE202021004113U1 (https=) |
| ES (2) | ES2936277B2 (https=) |
| GB (2) | GB2607514B (https=) |
| HR (1) | HRP20251116T1 (https=) |
| HU (1) | HUE21846991T1 (https=) |
| IL (1) | IL300027A (https=) |
| MX (1) | MX2023000798A (https=) |
| PL (1) | PL4051265T3 (https=) |
| RS (1) | RS67201B1 (https=) |
| SM (1) | SMT202500351T1 (https=) |
| WO (1) | WO2022020242A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11124497B1 (en) | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| US11174231B1 (en) | 2020-06-09 | 2021-11-16 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| PH12022553378A1 (en) * | 2020-06-10 | 2024-03-25 | Univ Leuven Kath | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| JP2023533016A (ja) | 2020-07-11 | 2023-08-01 | ファイザー・インク | 抗ウイルス性ヘテロアリールケトン誘導体 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| US12540141B2 (en) | 2020-11-23 | 2026-02-03 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| KR20230124583A (ko) | 2020-11-23 | 2023-08-25 | 이난타 파마슈티칼스, 인코포레이티드 | 신규한 스피로피롤리딘 유래 항바이러스제 |
| RS66213B1 (sr) * | 2021-04-16 | 2024-12-31 | Fujian Akeylink Biotechnology Co Ltd | Jedinjenje kratkog peptida prolina modifikovanog prstenom i upotreba istog |
| WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
| US12398147B2 (en) | 2021-05-11 | 2025-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| WO2022251615A1 (en) | 2021-05-28 | 2022-12-01 | Arun K Ghosh | Compounds for the treatment of sars |
| US20230033285A1 (en) * | 2021-06-16 | 2023-02-02 | The Scripps Research Institute | Protease Inhibitors for Treatment of Coronavirus Infections |
| AU2022306289A1 (en) | 2021-07-09 | 2024-01-18 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| US11912714B2 (en) | 2021-11-12 | 2024-02-27 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11858945B2 (en) | 2021-11-12 | 2024-01-02 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| US11919910B2 (en) | 2021-11-12 | 2024-03-05 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023088418A1 (en) * | 2021-11-20 | 2023-05-25 | Fochon Biosciences, Ltd. | Compounds as sars-cov-2 inhibitors |
| WO2023107419A1 (en) | 2021-12-08 | 2023-06-15 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| US12145941B2 (en) | 2021-12-08 | 2024-11-19 | Enanta Pharmaceuticals, Inc. | Heterocyclic antiviral agents |
| WO2023116811A1 (zh) * | 2021-12-22 | 2023-06-29 | 福建广生中霖生物科技有限公司 | 含β-胺基酮的短肽化合物及其应用 |
| TW202334123A (zh) * | 2021-12-31 | 2023-09-01 | 大陸商蘇州愛科百發生物醫藥技術有限公司 | 用於預防和治療冠狀病毒感染的化合物及其偶聯物和方法 |
| WO2023137007A1 (en) | 2022-01-11 | 2023-07-20 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1h-indole-2-carboxylic acid |
| CN118451090A (zh) * | 2022-01-13 | 2024-08-06 | 海南先声药业有限公司 | 一种酰胺类抗病毒化合物 |
| US11760722B2 (en) | 2022-01-18 | 2023-09-19 | Ascletis Bioscience Co., Ltd. | Inhibitors of cysteine proteases and methods of use thereof |
| CN114230504B (zh) * | 2022-02-24 | 2022-06-03 | 南京桦冠生物技术有限公司 | 一种吡咯烷酮中间体的合成方法 |
| CN116768967A (zh) * | 2022-03-07 | 2023-09-19 | 广州谷森制药有限公司 | 氘代内酰胺类化合物及其制备方法、组合物和用途 |
| CN117143082A (zh) * | 2022-03-07 | 2023-12-01 | 广州国家实验室 | 用作3c样蛋白酶抑制剂的氮杂双环[3.1.0]己烷衍生物 |
| CN114957383B (zh) * | 2022-04-01 | 2024-12-31 | 中国科学院上海药物研究所 | 一种拟肽类化合物及其制备方法、药物组合物和用途 |
| WO2023196307A1 (en) | 2022-04-05 | 2023-10-12 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| CN117164582A (zh) * | 2022-05-31 | 2023-12-05 | 周龙兴 | 一种蛋白酶抑制剂及其药物组合物和用途 |
| CN117362213A (zh) * | 2022-06-30 | 2024-01-09 | 武汉瑞晟药业有限公司 | 一种吡咯烷酮中间体的制备方法 |
| WO2024059087A1 (en) * | 2022-09-13 | 2024-03-21 | Takeda Pharmaceutical Company Limited | 3-(1h-indole-2-carbonyl)-6,6-dimethyl-n-((s)-1-oxo-3-((s)-2-oxopyrrolidin-3-yl)p ropan-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide derivatives as mpro inhibitors for the treatment of coronavirus infections |
| WO2024107778A1 (en) * | 2022-11-15 | 2024-05-23 | Takeda Pharmaceutical Company Limited | Novel protease inhibitors for treatment of coronavirus infections |
| KR20250109233A (ko) * | 2022-11-22 | 2025-07-16 | 머크 샤프 앤드 돔 엘엘씨 | 코로나바이러스 감염을 치료 또는 예방하기 위한 프로테아제 억제제로서의 2-아미노-n-(4-아미노-3,4-디옥소-1-(2-옥소피롤리딘-3-일)부탄-2-일)벤즈아미드 유도체 |
| EP4501942A1 (en) | 2023-08-02 | 2025-02-05 | Consejo Superior De Investigaciones Científicas (CSIC) | Peptidomimetics with antiviral activity |
| WO2025125695A2 (en) | 2024-12-17 | 2025-06-19 | Medchemica Consultancy Ltd | Chemical compoundsid50000167790940 p. doc 2025-05-07 filing no.:19 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
| US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
| DK1385870T3 (da) * | 2000-07-21 | 2010-07-05 | Schering Corp | Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus |
| EP1628674A2 (en) | 2003-05-06 | 2006-03-01 | Cytovia, Inc. | Protease inhibitors for coronaviruses and sars-cov and the use thereof |
| ATE382686T1 (de) | 2003-05-13 | 2008-01-15 | Univ Luebeck | Kristallstruktur von der humanen coronavirus 229e hauptproteinase und deren verwendung zur entwicklung von sars-inhibitoren |
| US20060014821A1 (en) * | 2003-08-27 | 2006-01-19 | Agouron Pharmaceuticals, Inc. | Inhibitors of SARS 3C like protease |
| US7462594B2 (en) | 2003-12-31 | 2008-12-09 | Taigen Biotechnology Co., Ltd. | Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases |
| WO2005113580A1 (en) | 2004-05-21 | 2005-12-01 | Pfizer Inc. | Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| WO2006061714A2 (en) | 2004-12-09 | 2006-06-15 | Pfizer Inc. | Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| EP1783228A1 (en) | 2005-11-08 | 2007-05-09 | ETH Zürich | Recombinant expression of multiprotein complexes using polygenes |
| ES2514316T3 (es) | 2005-11-22 | 2014-10-28 | Novartis Vaccines And Diagnostics, Inc. | Partículas similares a virus (VLPs) de Norovirus y Sapovirus |
| SG175602A1 (en) | 2006-07-05 | 2011-11-28 | Catalyst Biosciences Inc | Protease screening methods and proteases identified thereby |
| WO2010141801A2 (en) | 2009-06-05 | 2010-12-09 | Cellular Dynamics International, Inc. | Reprogramming t cells and hematophietic cells |
| US9008723B2 (en) * | 2010-01-08 | 2015-04-14 | United States Foundation For Inspiration And Recognition Of Science And Technology | Wireless adapter |
| WO2011159684A2 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
| CA2850003C (en) | 2011-09-27 | 2020-01-07 | Kansas State University Research Foundation | Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses |
| CA2858613A1 (en) | 2011-12-29 | 2013-08-08 | Atyr Pharma, Inc. | Aspartyl-trna synthetase-fc conjugates |
| US9828342B2 (en) | 2012-02-24 | 2017-11-28 | City Of Hope | Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereof |
| EP2844249A4 (en) | 2012-05-02 | 2016-03-09 | Univ Kansas State | MACROCYCLIC AND PEPTIDOMIMETIC COMPOUNDS AS VIRUZIDES AGAINST 3C OR 3C LIKE PROTEASES OF PICORNIVERS, CALICIVIRES AND CORONA VIRUSES |
| WO2014040129A1 (en) | 2012-09-12 | 2014-03-20 | The University Of Queensland | Protease-based biosensor |
| BR112015016651A2 (pt) | 2013-01-11 | 2017-07-11 | Impossible Foods Inc | réplica de queijo não láctea compreendendo um coacervado |
| US20160068820A9 (en) | 2013-02-08 | 2016-03-10 | The United States Of America, As Represented By The Secretary Of Agriculture | Novel Nylanderia Pubens Virus |
| ES2708565T3 (es) | 2013-03-15 | 2019-04-10 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
| EP3925618A1 (en) | 2013-07-29 | 2021-12-22 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| EP3044322A4 (en) | 2013-09-12 | 2017-09-06 | The University Of Queensland | Bimolecular protease-based biosensor |
| GB201320351D0 (en) | 2013-11-18 | 2014-01-01 | Erasmus Universiteit Medisch Ct | Method |
| PL3134432T3 (pl) | 2014-04-25 | 2020-10-19 | Bluebird Bio, Inc. | Promotor mnd chimeryczne receptory antygenowe |
| US10023879B2 (en) | 2014-06-04 | 2018-07-17 | Fate Therapeutics, Inc. | Minimal volume reprogramming of mononuclear cells |
| SI3151672T1 (sl) | 2014-06-06 | 2021-03-31 | Bluebird Bio, Inc. | Izboljšani T-celični sestavki |
| US10017463B2 (en) | 2014-07-21 | 2018-07-10 | Brandeis University | Inhibitors of deubiquitinating proteases |
| GB201413020D0 (en) | 2014-07-23 | 2014-09-03 | Pribright The Inst | Coronavirus |
| US9328147B2 (en) | 2014-09-05 | 2016-05-03 | Chung Yuan Christian University | Recombinant baculovirus vector and uses thereof |
| HRP20191873T1 (hr) | 2014-12-12 | 2020-01-24 | Bluebird Bio, Inc. | Kimerni antigenski receptori |
| WO2016138421A1 (en) | 2015-02-27 | 2016-09-01 | Iowa State University Research Foundation, Inc. | Porcine epidemic diarrhea virus strains and immunogenic compositions therefrom |
| US10784994B2 (en) | 2015-08-21 | 2020-09-22 | Lg Electronics Inc. | Method for transmitting information for LTE-WLAN aggregation system and a device therefor |
| WO2017044507A2 (en) | 2015-09-08 | 2017-03-16 | Sirnaomics, Inc. | Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection |
| EP3426674A4 (en) | 2016-03-09 | 2019-08-14 | Blade Therapeutics, Inc. | CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US9975885B2 (en) | 2016-04-28 | 2018-05-22 | Purdue Research Foundation | Broad-spectrum non-covalent coronavirus protease inhibitors |
| US11021513B2 (en) | 2016-05-13 | 2021-06-01 | Emory University | Peptidomimetics for the treatment of norovirus infection |
| WO2017222935A1 (en) | 2016-06-20 | 2017-12-28 | Kansas State University Research Foundation | Small molecule therapeutic inhibitors against picornaviruses, caliciviruses, and coronaviruses |
| WO2018023054A1 (en) | 2016-07-28 | 2018-02-01 | Kansas State University Research Foundation | Protease transition state inhibitor prodrugs |
| TW201817714A (zh) | 2016-08-30 | 2018-05-16 | 英商葛蘭素史密斯克藍智慧財產權有限公司 | 抑制3c及3cl蛋白酶之化合物及其使用方法 |
| WO2018064119A1 (en) | 2016-09-28 | 2018-04-05 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
| MA48797A (fr) | 2017-05-25 | 2020-04-08 | Bluebird Bio Inc | Variants de l'endonucléase cblb , compositions et procédés d'utilisation |
| WO2020072059A1 (en) | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
| BR112021024310A2 (pt) | 2019-06-05 | 2022-02-15 | Univ Emory | Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus |
| US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
| WO2021205296A1 (en) | 2020-04-05 | 2021-10-14 | Pfizer Inc. | Method of treating covid-19 |
| WO2021207409A2 (en) | 2020-04-08 | 2021-10-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of sars-cov-2 viral replication and uses thereof |
| AU2021254045A1 (en) | 2020-04-10 | 2022-10-13 | Cocrystal Pharma, Inc. | Inhibitors of norovirus and coronavirus replication |
| WO2021206877A1 (en) | 2020-04-10 | 2021-10-14 | Cocrystal Pharma, Inc. | Inhibitors of norovirus and coronavirus replication |
| US11124497B1 (en) | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| EP4146267A1 (en) * | 2020-05-08 | 2023-03-15 | The Board of Trustees of the Leland Stanford Junior University | Protease inhibitors for treatment or prevention of coronavirus disease |
| US11174231B1 (en) | 2020-06-09 | 2021-11-16 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| BR112021023814A2 (pt) * | 2020-06-09 | 2022-12-20 | Pardes Biosciences Inc | Inibidores de proteases de cisteína e métodos de uso das mesmas |
| PH12022553378A1 (en) * | 2020-06-10 | 2024-03-25 | Univ Leuven Kath | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| JP2023533016A (ja) * | 2020-07-11 | 2023-08-01 | ファイザー・インク | 抗ウイルス性ヘテロアリールケトン誘導体 |
| WO2022020711A1 (en) | 2020-07-24 | 2022-01-27 | The Texas A&M University System | Sars-cov-2 main protease inhibitors |
| US10959969B1 (en) | 2020-07-24 | 2021-03-30 | Lanny L Johnson | Methods of treating SARS Cov-2 virus with protocatechuic acid |
| CN115960088B (zh) * | 2020-07-31 | 2024-07-26 | 四川大学 | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 |
| US11351149B2 (en) * | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| RS66213B1 (sr) * | 2021-04-16 | 2024-12-31 | Fujian Akeylink Biotechnology Co Ltd | Jedinjenje kratkog peptida prolina modifikovanog prstenom i upotreba istog |
| WO2022251615A1 (en) * | 2021-05-28 | 2022-12-01 | Arun K Ghosh | Compounds for the treatment of sars |
| WO2022256434A1 (en) * | 2021-06-02 | 2022-12-08 | ACEA Therapeutics, Inc. | Protease inhibitors as antivirals |
| EP4159211A4 (en) * | 2021-07-15 | 2024-10-30 | National Center for Global Health and Medicine | ASSOCIATED WITH PHYSIOLOGICAL ACTIVITY SUCH AS ANTIVIRAL ACTIVITY |
-
2021
- 2021-07-19 US US17/379,409 patent/US20220033383A1/en not_active Abandoned
- 2021-07-19 PL PL21846991.4T patent/PL4051265T3/pl unknown
- 2021-07-19 HU HUE21846991A patent/HUE21846991T1/hu unknown
- 2021-07-19 ES ES202290062A patent/ES2936277B2/es active Active
- 2021-07-19 ES ES21846991T patent/ES2922973T3/es active Active
- 2021-07-19 KR KR1020237005438A patent/KR20230069090A/ko active Pending
- 2021-07-19 DE DE202021004113.3U patent/DE202021004113U1/de active Active
- 2021-07-19 IL IL300027A patent/IL300027A/en unknown
- 2021-07-19 WO PCT/US2021/042193 patent/WO2022020242A1/en not_active Ceased
- 2021-07-19 EP EP25185114.3A patent/EP4635972A3/en active Pending
- 2021-07-19 RS RS20250906A patent/RS67201B1/sr unknown
- 2021-07-19 BR BR112022026899A patent/BR112022026899A2/pt not_active Application Discontinuation
- 2021-07-19 EP EP21846991.4A patent/EP4051265B1/en active Active
- 2021-07-19 CN CN202180059223.3A patent/CN116348477A/zh active Pending
- 2021-07-19 GB GB2211934.1A patent/GB2607514B/en active Active
- 2021-07-19 HR HRP20251116TT patent/HRP20251116T1/hr unknown
- 2021-07-19 DE DE112021000413.1T patent/DE112021000413B4/de active Active
- 2021-07-19 JP JP2023504063A patent/JP7795521B2/ja active Active
- 2021-07-19 DE DE21846991.4T patent/DE21846991T1/de active Pending
- 2021-07-19 SM SM20250351T patent/SMT202500351T1/it unknown
- 2021-07-19 MX MX2023000798A patent/MX2023000798A/es unknown
- 2021-07-19 GB GB2306834.9A patent/GB2619610B/en active Active
- 2021-07-19 CA CA3173964A patent/CA3173964A1/en active Pending
- 2021-07-19 AU AU2021313130A patent/AU2021313130A1/en active Pending
- 2021-10-21 US US17/506,981 patent/US20220041652A1/en not_active Abandoned
- 2021-11-09 US US17/522,176 patent/US11358953B2/en active Active
-
2023
- 2023-01-11 CO CONC2023/0000199A patent/CO2023000199A2/es unknown
- 2023-01-18 CL CL2023000167A patent/CL2023000167A1/es unknown
-
2025
- 2025-12-19 JP JP2025266591A patent/JP2026053472A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023000199A2 (es) | Péptidos funcionalizados como agentes antivirales | |
| CL2023001476A1 (es) | Nuevos agentes antivirales derivados de la espiropirrolidina | |
| CO2023002852A2 (es) | Péptidos funcionalizados como agentes antivirales | |
| MX2023005983A (es) | Nuevos agentes antivirales derivados de la espiropirrolidina. | |
| SA521430792B1 (ar) | مركبات مضادة للفيروسات محتوية على نيتريل | |
| CR20230616A (es) | Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn) | |
| GEAP202316298A (en) | Highly active compounds against covid-19 | |
| PE20240881A1 (es) | Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t | |
| MX2022003984A (es) | Compuestos heterociclicos antivirales. | |
| AR128931A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| UY39864A (es) | Nuevos agentes antivirales derivados de espiropirrolidina | |
| UY39032A (es) | Compuestos heterocíclicos como agentes antivirales | |
| UY38614A (es) | Derivados de benzodiazepinas como inhibidores del rsv | |
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| DOP2023000060A (es) | Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención | |
| CL2022000781A1 (es) | Tratamientos cognitivos medicinales | |
| GEAP202516786A (en) | 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)butan-2-yl)benzamide derivatives as protease inhibitors for treating or preventing coronavirus infection | |
| MX2025013861A (es) | Compuestos anti virus de la inmunodeficiencia humana (vih) | |
| MX2024001377A (es) | Nuevos agentes antivirales derivados de la espiropirrolidina. | |
| UY39862A (es) | Nuevos agentes antivirales derivados de espiropirrolidina | |
| AR126501A1 (es) | Nuevos agentes antivirales derivados de espiropirrolidina | |
| AR126482A1 (es) | Agentes antivirales derivados de espiropirrolidina | |
| MX2024011932A (es) | Combinaciones farmaceuticas y metodos de uso del compuesto de amino-pirrolopirimidinona | |
| CL2021001093A1 (es) | Compuestos, composiciones, y métodos para modular la actividad cdk9 |